

THE ROLE OF ISABA1 AND OXA CARBAPENEMASE GENES, in CARBAPENEM RESISTANT AMONG ACINETOBACTERBAUMANNII ISOLATED from ZAGAZIG HOSPITALS

Yosra A. Osama^{#1}, Manal M. El-Amin² & Hoda A. Ibraheem³

Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Egypt.

Abstract:

Introduction: “Red alert” pathogen this is how *Acinetobacterbaumannii* identified nowadays in healthcare facilities, due to its extensive antibiotic resistance pattern. Multidrug-resistant *A. baumannii* infections are best treated with Carbapenems. The aim of the study is to estimate the numbers of bla_{oxa} and ISAb₁ producing strains among carbapenem-resistant *A. baumannii* clinical isolates.

Method: identification of *A. baumannii* was carried out by Matrix-assisted laser desorption ionization–time of flight mass spectrometry, VITEK 2 compact was used to assess antimicrobial sensitivities and E test used to reconfirm susceptibility to imipenem, multiplex PCR for class D β lactamase genes detection. Mapping PCR carried out in order to estimate the presence of ISAb₁ in relation to blaOXA-23 and blaOXA-51 genes.

Results: Fourty eight *A. baumannii* strains were isolated from different anatomical sites from surgical patients in Zagazig University hospital. Antibiogram showed that 81.3% (n=39) of the isolates were resistant to Imipenem, while 9 isolates were susceptible (18.7%). Of 39 resistant isolates to Imipenem, ISAb₁ was detected in 35 isolates (89.7%). 34 isolates carried blaOXA-23 gene, all contained ISAb₁/blaOXA-23 genes, and 20 contained ISAb₁/blaOXA-51 genes. Resistant isolates to carbapenems all had ISAb₁ upstream of blaOXA-23 gene, While ISAb₁ upstream of blaOXA-51 found in both susceptible and resistant isolates.

Conclusion: The ISAb₁/blaOXA-23 genes were prevalent among the carbapenem-resistant *A. baumannii* isolates and may be responsible for carbapenems resistance. The present study revealed that the existence of ISAb₁/blaOXA-51 in *A. baumannii* isolates was not conclusive to carbapenems resistance.

Keywords: *Acinetobacterbaumannii*, ISAb₁, bla_{oxa}, carbapenems resistance.

INTRODUCTION

Acinetobacterbaumannii, was considered low pathogenic organism, but now days considered to have principle role in both health care- and community-acquired infections. It is resistant to almost most antibiotics by means of genetic exchange on one hand, on the other hand it can contaminate hospital environments for prolonged period in tough conditions (walls, surfaces, and medical devices) (Pourhajibagher et al., 2016).

β -lactam resistant *A. baumannii*; carbapenems are the most choosable antibiotics to treat infections caused by it. However, limited choices of treatment due to marked increase in carbapenems resistance are major problem (Kim et al., 2013). There are many mechanisms responsible for carbapenem resistance, however, class D beta-lactamases (CHDLs)

production remain the most common and leading mechanisms in Carbapenem hydrolyzing among *A. baumannii* isolates (Lin et al., 2014). However, their expression is often greater by the insertion of an upstream IS, which enriches expression by providing a strong promoter, causing high levels of resistance (Mugnier et al., 2009). Insertion Sequence *ISAbal*, has been detected in *A. baumannii* known to have inverted repeat sequences (IRs) 11-bp flanked by direct repeats 9-bp of the target sequence (Nowak et al., 2012). The (insertion sequences) IS have a role for β -lactamase production by acting as strong promoters and have a role to obtain other challenging phenotypes in *A. baumannii* (Gheorghe et al., 2015).

The aim of this study is to estimate the frequency of bla_{oxa} producing strains among carbapenem-resistant *A. baumannii* isolates and analyze the existence of *ISAbal/blaOXA-23* and *ISAbal/blaOXA-51* genes, also investigate its role in resistance.

MATERIALS AND METHODS

Bacterial isolates

A total of non duplicate 48 clinical isolates were included in this study recovered from wound swab, pus, peripheral blood culture, peritoneal fluid, sputum, cvp tips and urine from surgical ICU and surgery departments of Zagazig University Hospitals over the period from March 2018 to July 2019. The isolates were identified as *Acinetobacter baumannii* complex by Matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) up to the species level and furthermore confirmed as *Acinetobacter baumannii* using intrinsically located *blaOXA-51* gene by PCR (Turton et al., 2006).

Antibiotic susceptibility testing

Vitek 2 compact System (GN-222) for gram negative bacilli (Biomerieux, Inc, Durham, USA) used for Antibiotic sensitivity testing, according to the guidelines of Clinical and Laboratory Standards Institute (CLSI, 2012), Susceptibility to imipenem was reconfirmed by E-test strips (Biomerieux, France).

Molecular Characterization

DNA extraction from colonies by using i-genomic BYF DNA Extractin Mini Kit, then DNA amplification was done by:

- Multiplex PCR used for Detecting *ClasD OXA*-Carbapenemase genes: To detect the existence of intrinsically located *blaOXA-51* gene and the existence of other acquired OXA genes namely *blaOXA-23*, *blaOXA-58* and *blaOXA-24/40*. Multiplex PCR was performed using thermal cycler (Applied Biosystems thermal cycler) with cycling condition of initial denaturation step at 94 °C for 3 min followed by Denaturation at 94 °C for 1 min for 30 cycles. Annealing at 52 °C for 30s. Extension at 72 °C for 1 min and finally extension at 72 °C for 10 min (Woodford et al., 2006).
- Subsequent Uniplex PCR, in order to detect insertion sequence (IS) element, *ISAbal*. To plot the location of the IS element in relation to the *blaOXA-23* and *blaOXA-51*-like genes by using two types of primers. First, the forward primer of *ISAbal* gene and the reverse primer of *blaOXA-51* gene, the second is the same forward primer but reverse primer of *blaOXA-23* gene. Detection is read at 1.2 kb and 1.4 kb of the amplified product respectively. Using the subsequent conditions: initial denaturation at 95 °C for 2 min, 30 cycles of 95 °C for 10 s, 53 °C for 40 s for annealing then extension at 72 °C for 3 min, at last final extension at 72 °C for 60 s (Martinez et al., 2012).

Primers used in PCR reaction listed in **(table1)**. Briefly, for PCR amplification, reaction mixture containing 5 ul of extracted DNA , 1ul of each forward and reverse diluted primers solutions, 15ul of ready to use (Dream TaqTM Green PCR Master Mix (2X) thermoscientific were used following manufacture's instructions.

PCR products detection:

After amplification, products detected on 2 % agarose gel stained with ethidium bromide then visualized with trans-illuminator.

Table (1): Sequences of primers used in PCR:

Gene	Primer	Sequence (5' to 3')	Amplicon size(bp)	Referances	
OXA51	OXA51F	TAA TGC TTT GAT CGG CCT TG	353bp	Woodford et al., 2006	
	OXA51R	TGG ATT GCA CTT CAT CTT GG			
OXA23	OXA23LF	GAT CGG ATT GGA GAA CCA GA	501 bp		
	OXA23LR	ATT TCT GAC CGC ATT TCC AT			
OXA 24	OXA24LF	GGT TAG TTG GCC CCC TTA AA	246bp		
	OXA24LR	AGT TGA GCG AAA AGG GGA TT			
OXA58	OXA58LF	AAG TAT TGG GGC TTG TGC TG	599bp		
	OXA58LR	CCC CTC TGC GCT CTA CAT AC			
ISAbal	ISAbal1F	CAC GAA TGC AGA AGT TG	549bp		Segal et al., 2005
	ISAbal1R	CGA CGA ATA CTA TGA CAC			

RESULTS

The forty eight isolates included in this study were recovered from pus (**n=28**), wound swab (**n=4**), peripheral blood culture (**n=3**), Body fluids (**n=5**), sputum (**n=6**), cyp tips (**n=1**) and urine (**n=1**).

Antimicrobial susceptibility

MIC for carbapenems antibiotics was determined by using Vitek 2 System. It was found that 39 isolates (81.3%) of all isolates were resisted to carbapenem antibiotic (Imipenem) used in this study, while 9 isolates (18.7%) were sensitive to this antibiotic. Imipenem sensitivity results in these isolates were reconfirmed by E test and called resistant when MIC ($\geq 8 \mu\text{g/ml}$) according to CLSI guidelines (CLSI., 2020).

Detection of class D OXA carbapenemases genes and insertion sequence

Detection of the OXA carbapenemases genes including (blaOXA-51, blaOXA-23, blaOXA24/40 and blaOXA-58) in carbapenem-resistant isolates were carried out using a multiplex PCR assay (**figure1**). BlaOXA-51 gene was found in all isolates, while blaOXA-23 gene was detected in 34 out of 39 resistant isolates. BlaOXA-24 gene was found in 5/39 while blaOXA-58 gene was absent in all isolates (**table 2**).

Mapping PCR

The dominance of ISAbal element (35) and its association with blaOXA-23 or blaOXA-51 genes or with both were investigated (**Table 3**).

Table (2): Distribution of bla OXA and ISAbal among *A.baumannii* isolates

Genetic elements	CRAB (n=39)		CSAB (n=9)		P#
	No	%	No	%	
bla _{oxa} - 51like	39	100%	9	100%	---
bla _{oxa} - 23 like	34	87.2%	2	22.2%	<0.001**
bla _{oxa} -24/40 like	5	12.8%	0	0%	0.67 NS
bla _{oxa} - 58 like	0	0%	0	0%	---
ISAbal	35	89.7%	2	22.2%	<0.001**

#: chi square or Fisher exact corrected test

NS: Non significant (P>0.05)

** : highly significant (P<0.01)

Table (3):Distribution of genetic element ISAbal after doing subsequent PCR:

Genetic elements	CRAB (n=39)		CSAB (n=9)		P#
	No	%	No	%	
bla _{oxa} - 51	39	100%	9	100%	---
bla _{oxa} - 51+ISAbal	20	51.3%	2	22.2%	0.23 NS
bla _{oxa} - 23	34	87.2%	2	22.2%	<0.001**
bla _{oxa} -23+ISAbal	34	87.2%	0	0%	<0.001**

The current study revealed that ISAbal was detected in 35 (89.7%) of resistant isolates and in 2 of sensitive isolates(22.2%). In carbapenem-resistant isolates, the results revealed presence of blaOXA-51/ISAbal in 20 isolates(51.3%) while blaOXA-23/ISAbal was found in 34 isolates (87.2%), in other word, all resistant isolates which contained blaOXA23 gene carried ISAbal upstream of this gene. In susceptible isolates, it was found that blaOXA-51/ISAbal present in 2/9 isolates (22.2%) while blaOXA-23/ISAbal was not present in any susceptible isolate in spite of the existence of 2 blaOXA23 genes among them. The current study demonstrated that blaOXA-51/ISAbal was found in both carbapenem-resistant and susceptible *A.baumannii* isolates.

ISAbal shown to be located with blaOXA-23 gene at the promoter region by PCR mapping in 34 carbapenem-resistant isolates; these amplicons were 1.4 kbp in size. 20 of resistant isolates and 2 of susceptible isolates also had ISAbal at the promoter region of blaOXA-51 gene. Detected at 1.2 kbp in size.




Figure (1): Gel electrophoresis for detection of PCR multiplex with OXA genes primers. Lane (M), DNA ladder(molecular size 100 bp). Lanes (1-6) show positive results at 353 bp for OXA 51 and positive results at 501bp for OXA 23, Lanes (2-4) show positive results at 249 bp for OXA 24 while no OXA 58 at 599 bp was found.

DISCUSSION

High risk of *Acinetobacter baumannii*, mostly in ICUs now emerged because of the striking increased number of nosocomial infections caused by it globally(Garnacho-Montero et al.,

2010). Mostly, due to the unreasonable use of antibiotics, *A. baumannii* has become resistant to most antimicrobial classes, leading to the dominance of multi-drug resistant strains particularly among hospital patients. This result in limited options for treatment of infections caused by resistance isolates of *A. baumannii* which lead to higher morbidity and mortality rates (Fattouh and El-din et al., 2014).

Class D beta-lactamases (CHDLs) production remain the most common and leading mechanisms in Carbapenemhydrolyzing among *A. baumannii* isolates, despite presence of many mechanisms responsible for carbapenem resistance, (Lin et al., 2014).

Detection of oxacillinases among resistant strains is critical to help the choice of correct course of therapy. CHDLs can be either intrinsic/chromosomal or acquired (Abbott., 2013).

In the current study, according to Vitek results, most of the isolates (**81.3%**) were imipenem resistant with MIC $\geq 8 \mu\text{g/ml}$ (CLSI., 2020). Imipenem resistance was reconfirmed by measuring by E-test strips (bioMérieux), while (**18.7%**) of isolates were sensitive to imipenem.

Despite being burdensome, the E-test is the standard method. According to study's results E-test and VITEK 2 agreed to high degree. When trying to choose substitution for for treating Acinetobacter infections while waiting for E-test results, VITEK 2 results are acceptable (Altun et al., 2016).

In Egypt, 70% to 100% are resistance rates for imipenem in *A. baumannii* isolates. This denote the magnitude of the problem in treating MDR *A. baumannii* (Al-Agamy et al., 2014, Ahmed et al., 2011, Nasr and Attalah, 2012, -Al-Hassanet al., 2013-El-Bannah et al., 2018).. The last resort of treatment are colistin and tigecycline (Al-Agamy et al., 2014).

Due to sever side effect of colistin, this may lead to infrequent use. In the present study, all the tested isolates, remain sensitive to colistin with sensitivity of 100%. This agree with prior studies in Egypt, in which colistin retain it's activity against 95% in (Al-Agamy et al., 2014) and 100% in (Fouad et al., 2013) of the tested isolates.

In order to proof that *A. baumannii* has a natural intrinsic blaOXA-₅₁ like responsible for carbapenem resistance. Multiplex PCR performed in this study show that all the 48 clinical isolates were positive for bla OXA-₅₁-like gene. Similar results were also obtained by previous studies (Al-Agamy et al., 2014, Abouelfetouh et al., 2019, Ben Mahmod et al., 2018, Kobs et al., 2016, Owrang et al., 2018, Cicek et al., 2013, El-Bannah et al., 2018).

BlaOXA-23 was the most CHDL-encoding gene prevalent in carbapenem resistant *A. baumannii* with predominance rate of 87.2% (34/39), this has been recently reported in numerous studies that blaOXA-23 is the most frequent resistant gene identified among carbapenem-resistant *A. baumannii* isolates (Abbott et al., 2013, Al-Agamy et al., 2014, Abouelfetouh et al., 2019, Ben Mahmod et al., 2018, Kobs et al., 2016, Owrang et al., 2018, Cicek et al., 2013, Al-Hassanet al., 2013, Fouad et al., 2013, El-Bannah et al., 2018). blaOXA-_{24/40} have been detected in 12.8% of the isolates in this study, compared to previous results obtained in Egypt, in which blaOXA-_{24/40} have detected in 7.5% of the islates (Al-Agamy et al., 2014) and in 2.9% of the isolates (Lin et al., 2014). However, Abouelfetouh et al. (2019) state that blaOXA-40 was absent in all tested isolates. BlaOXA-_{24/40} have mostly

been found in Asia, Europe and other areas in the world (Cicek et al., 2013, Abbott et al., 2013, Zhang et al., 2015).

On contrary to our results, many studies reported presence of blaOXA-58 in *A. baumannii* tested isolates in different places of the world including Italy, UK, Kuwait, Argentina, Spain, USA, and Turkey and also in Egypt (Abouelfetouh et al., 2019).

We found that ISAbal was present in 89.7% of carbapenem resistant isolates, in all CRAB isolates positive for *blaOXA-23-like* gene (n=34), all had ISAbal, in comparison with the sensitive two isolates where *blaOXA-23* was not associated with ISAbal. This close relation between ISAbal and *blaOXA-23-like*, was also observed in Kobs et al. (2016), explains the continuing dependability of this resistance mechanism in cross-infection occurring at hospital. So, the presence of *blaOXA-23-like* lacking ISAbal promoter sequence might be inadequate to hydrolyse carbapenems, as reported by Carvalho et al., 2011.

However, imipenem-susceptible *A. baumannii* isolates (n=2) having *blaOXA-23* gene, may suppose silent spread in hospital setting and highlight the threat of undiagnosed reservoirs of carbapenemase genes (Carvalho et al., 2011).

It was proved that both carbapenem resistant and sensitive isolates of *A. baumannii* contained ISAbal element in association with blaOXA-51, and ISAbal/blaOXA-51 association was found in 51.3% of carbapenem resistant *A. baumannii* isolates. Pagano et al. (2012) established that ISAbal element was not correlated with carbapenem resistance in *A. baumannii* when found upstream blaOXA-51.

Furthermore, five isolates of *A. baumannii* were carbapenem unresponders, it only possess *blaOXA-51-like* gene, while other genes were absent. The reason of carbapenem-unresponsiveness in these isolates other than resistance genes, may be caused by modification of penicillin binding proteins, AmpC stable derepression, overexpression of efflux pump, loss of porins and decreased permeability, or insertion of ISAbal at promoter region of blaOXA-51-like gene (Turton et al., 2006).

CONCLUSION

The ISAbal/blaOXA-23 genes were the most common gene association among the carbapenem-unresponders *A. baumannii* isolates and carbapenem unresponsiveness may be due to ISAbal at promoter sequence of blaOXA-23 gene mostly. The present study revealed that the presence of ISAbal/blaOXA-51 in *A. baumannii* isolates was not conclusive to carbapenem resistance.

Conflict of interest

The authors declare no conflict of interest

This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sector.

REFERENCES

- [1] Pourhajibagher M, Hashemi FB, Pourakbari B, Aziemzadeh M, Bahador A (2016): Antimicrobial resistance of *Acinetobacter baumannii* to imipenem in Iran: a systematic review and meta-analysis. *Open Microbiol J*; 10:32–42.
- [2] Kim DH, Choi JY, Kim HW, Kim SH, Chung DR, Peck KR, et al. (2013): Spread of carbapenem-resistant *Acinetobacter baumannii* global clone 2 in Asia and AbaR-type

- resistance islands. *Antimicrob Agents Chemother*; 57(11): 5239–46. doi: 10.1128/AAC.00633-13. [PubMed: 23939892].
- [3] Lin MF, Lan CY (2014): Antimicrobial resistance in *Acinetobacterbaumannii*: from bench to bedside. *World J Clin Cases*; 2(12): 787–814.
- [4] Mugnier PD, Poirel L, Nordmann P (2009): Functional analysis of insertion sequence ISAbal, responsible for genomic plasticity of *Acinetobacterbaumannii*. *J Bacteriol*; 191: 2414–2418.
- [5] Nowak P, Paluchowska P, Budak A (2012): Distribution of blaOXA genes among carbapenem-resistant *Acinetobacterbaumannii* nosocomial strains in Poland. *New Microbiol*; 35(3):317–25. [PubMed:22842601].
- [6] Gheorghe I, Novais A, Grosso F, Rodrigues C, Chifiriuc MC, Lazar V, Peixe L (2015): Snapshot on carbapenemase-producing *Pseudomonas aeruginosa* and *Acinetobacterbaumannii* in Bucharest hospitals reveals unusual clones and novel genetic surroundings for blaOXA-23. *J Antimicrob Chemother*; 70: 1016–1020.
- [7] Turton JF, Ward ME, Woodford N, Kaufmann ME, Pike R, Livermore DM, Pitt TL (2006): The role of ISAbal in expression of OXA carbapenemase genes in *Acinetobacterbaumannii*. *FEMS Microbiol Lett*; 258: 72-77.
- [8] Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, Amyes SG, Livermore DM (2006): Multiplex PCR for genes encoding prevalent OXA carbapenemases in *Acinetobacter* spp. *Int J Antimicrob Agents*; 27: 351–353.
- [9] Martinez P, Mattar S (2012): Resistant *Acinetobacterbaumannii* carrying the ISAbal-blaOXA-23, 51 and ISAbal-blaADC-7 genes in Monteria, Colombia. *Braz J Microbiol*; 43(4): 1274–1280.
- [10] Segal H, Garry S, Elisha BG (2005). Is ISABA-1 customized for *Acinetobacter*? *FEMS Microbiol Lett*; 243:425–9.
- [11] CLSI (2020): Performance Standards For Antimicrobial susceptibility testing. 30th ed. CLSI supplement M100. Wayne, PA: Clinical And Laboratory Standards Institute ; 2020.
- [12] Garnacho-Montero J, Amaya-Villar R (2010): Multiresistant *Acinetobacterbaumannii* infections: epidemiology and management. *Curr Opin Infect Dis*; 23(4): 332–9.
- [13] Fattouh M, El-Din AN (2014): Emergence of carbapenem resistant *Acinetobacterbaumannii* in the intensive care unit in Sohag University hospital, Egypt. *Int J Curr Microbiol App Sci*; 3(4):732–44.
- [14] Altun S, Kocak ZT, Altun B, Onde U, Kinikli S, Demiröz AP (2016): Growing OXA-23 type strains among carbapenem-resistant *Acinetobacterbaumannii* and tigecycline as an alternate combination therapy. *Turkish J Med Sci*; 46: 1894-1899.
- [15] Ahmed SH, Abdelwahab SF, Hasanen AM, Mohammed DS (2011): Multidrug resistant Egyptian isolates of *Acinetobacterbaumannii*. *J Am Sci*; 7: 1013–9.
- [16] Al-Agamy MH, Khalaf NG, Tawfick MM, Shibl AM, El Kholy A (2014): Molecular characterization of carbapenem-insensitive *Acinetobacterbaumannii* in Egypt. *Int J Infect Dis*; 22: 49–54.
- [17] Al-Hassan L, El Mehallawy H, Amyes SG (2013): Diversity in *Acinetobacterbaumannii* isolates from paediatric cancer patients in Egypt. *Clin Microbiol Infect*; Feb 15. <http://dx.doi.org/10.1111/1469-0691.12143>. 30.
- [18] El Bannah AMS, Nawar NN, Hassan RMM, Salem STB (2018): Molecular Epidemiology of Carbapenem-Resistant *Acinetobacterbaumannii* in a Tertiary Care Hospital in Egypt: Clonal Spread of blaOXA-23. *Microb Drug Resist*; 24(3): 269–77.
- [19] Nasr RA, Attalah MF (2012): Molecular epidemiology of nosocomial *Acinetobacterbaumannii* isolates. *Nature and Science*; 10: 76–82.
- [20] Fouad M, Attia AS, Tawakkol WM, Hashem AM (2013): Emergence of carbapenem-resistant *Acinetobacterbaumannii* harboring the OXA-23 carbapenemase in intensive care

- units of Egyptian hospitals. *Int J Infect Dis*; 17: e1252–4. <http://dx.doi.org/10.1016/j.ijid.2013.07.012>.
- [21] Abouelfetouh A, Torky AS, Aboulmagd E (2019): Phenotypic and genotypic characterization of carbapenem-resistant *Acinetobacterbaumannii* isolates from Egypt. *Antimicrob Resist Infect Control*; 8: 185. doi: 10.1186/s13756-019-0611-6. [PubMed: 31832185]. [PubMed Central: PMC6868752].
- [22] Benmahmod AB, Said HS, Ibrahim RH (2018): Prevalence and mechanisms of carbapenem resistance among *Acinetobacterbaumannii* clinical isolates in Egypt. *Microb Drug Resist*; 25(4): 480-8.
- [23] Cicek AC, Saral A, Iraz M, Ceylan A, Duzgun AO, Peleg AY, et al. (2013): OXA- and GES-type β -lactamases predominate in extensively drug-resistant *Acinetobacterbaumannii* isolates from a Turkish University Hospital. *ClinMicrobiol Infect*; Jul 19. <http://dx.doi.org/10.1111/1469-0691.12338>.
- [24] Owrang M, Fallah F, Irani S, Rahbar M, Eslami G (2018): Identification and Isolation of Insertion Sequences, in Carbapenem Resistant Clinical Isolates of *Acinetobacterbaumannii* from Tehran Hospitals, *Jundishapur J Microbiol*; 11(6): e58251. doi: 10.5812/jjm.58251.
- [25] Kobs VC, Ferreira JA, Bobrowicz TA et al. (2016): The role of the genetic elements bla_{OXA} and IS Aba 1 in the *Acinetobactercalcoaceticus*/*Acinetobacterbaumannii* complex in carbapenem resistance in the hospital setting. *Rev Soc Bras Med Tro*; 49: 433–40.
- [26] Abbott I, Cerqueira GM, Bhuiyan S, Peleg AY (2013): Carbapenem resistance in *Acinetobacterbaumannii*: laboratory challenges, mechanistic insights and therapeutic strategies. *Expert Rev Anti-Infect Ther*; 11(4): 395–409.
- [27] Carvalho KR, Assef APDC, Santos LG, Pereira MJF, Asensi MD (2011): Occurrence of bla_{OXA}-23 gene in imipenem-susceptible *Acinetobacterbaumannii*. *MemInstOswaldo Cruz*; 106:505-506.
- [28] Pagano M, Martins AF, Machado AB, Barin, J, Barth AL (2012): Carbapenem-susceptible *Acinetobacterbaumannii* carrying the ISAbal1 upstream bla_{OXA}-51-like gene in Porto Alegre, southern Brazil. *Epidemiol Infect*; 141: 1-4.
- [29] Zhang X, Gu B, Mei Y, Wen Y, Xia W (2015): Increasing resistance rate to carbapenem among blood culture isolates of *Klebsiellapneumoniae*, *Acinetobacterbaumannii* and *Pseudomonas aeruginosa* in a university-affiliated hospital in China, 2004-2011. *J Antibiot (Tokyo)*; 68(2):115–20. doi: 10.1038/ja.2014.119. [PubMed: 25182483]